For other people named Andrew McKenzie, see Andrew McKenzie (disambiguation).

Andrew Neil James McKenzie FRS FMedSci[2] is a molecular biologist and group leader in the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB).[3]

Education

McKenzie was educated at the University of London where he was awarded a PhD for research on the immune response of the bluebottle fly (Calliphora vomitoria),[4] covering both humoral immunity and cell-mediated immunity.

Research and career

McKenzie's research investigates how the innate immune system and adaptive immune system protect the body from infection, but can also lead to inflammation and pathology.[2] He has defined and characterised how biological networks orchestrate responses to pathogens and how dysregulation of these biological pathways can lead to diseases such as asthma and allergy.[2][5]

His identification of the cytokine Interleukin 13 and the subsequent unearthing of its central role in allergic asthma led to his discovery of type-2 innate lymphoid cells (ILC2).[6][7] These cells secrete large quantities of cytokines and represent a new druggable biological target for intervention in inflammation and infection.[2]

Awards and honours

McKenzie was elected a Fellow of the Royal Society (FRS) in 2017[2] and a Fellow of the Academy of Medical Sciences (FMedSci) in 2011.[8]

References

  1. ^ McKenzie, Andrew N.J.; Ely, Barry; Sanderson, Colin J. (1991). "Mutated interleukin-5 monomers are biologically inactive". Molecular Immunology. 28 (1–2): 155–158. doi:10.1016/0161-5890(91)90099-6. ISSN 0161-5890. PMID 1901378.
  2. ^ a b c d e Anon (2017). "Dr Andrew McKenzie FMedSci FRS". royalsociety.org. London: Royal Society. Archived from the original on 2017-05-05. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --"Terms, conditions and policies | Royal Society". Archived from the original on 2016-11-11. Retrieved 2017-08-18.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  3. ^ Andrew N. J. McKenzie publications indexed by the Scopus bibliographic database. (subscription required)
  4. ^ McKenzie, Andrew Neil James (1988). Cellular and humoral aspects of the immune response of the larval stages of Calliphora vomitoria L. (Insecta: Diptera). london.ac.uk (PhD thesis). University of London. OCLC 940318709.
  5. ^ Neill, Daniel R.; Wong, See Heng; Bellosi, Agustin; Flynn, Robin J.; Daly, Maria; Langford, Theresa K. A.; Bucks, Christine; Kane, Colleen M.; Fallon, Padraic G.; Pannell, Richard; Jolin, Helen E.; McKenzie, Andrew N. J. (2010). "Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity". Nature. 464 (7293): 1367–1370. doi:10.1038/nature08900. ISSN 0028-0836. PMC 2862165. PMID 20200518.
  6. ^ Spits, Hergen; Artis, David; Colonna, Marco; Diefenbach, Andreas; Di Santo, James P.; Eberl, Gerard; Koyasu, Shigeo; Locksley, Richard M.; McKenzie, Andrew N. J.; Mebius, Reina E.; Powrie, Fiona; Vivier, Eric (2013). "Innate lymphoid cells — a proposal for uniform nomenclature". Nature Reviews Immunology. 13 (2): 145–149. doi:10.1038/nri3365. ISSN 1474-1733. PMID 23348417. (subscription required)
  7. ^ Newland, Stephen A.; Mohanta, Sarajo; Clément, Marc; Taleb, Soraya; Walker, Jennifer A.; Nus, Meritxell; Sage, Andrew P.; Yin, Changjun; Hu, Desheng; Kitt, Lauren L.; Finigan, Alison J.; Rodewald, Hans-Reimer; Binder, Christoph J.; McKenzie, Andrew N. J.; Habenicht, Andreas J.; Mallat, Ziad (2017). "Type-2 innate lymphoid cells control the development of atherosclerosis in mice". Nature Communications. 8: 15781. doi:10.1038/ncomms15781. ISSN 2041-1723. PMC 5467269. PMID 28589929. Open access icon
  8. ^ "Andrew McKenzie". Retrieved 22 January 2022.